Tom Lumbers

Dr. Tom Lumbers is a Principal Clinical Research Fellow at the UCL Institute of Health Informatics, an Honorary Consultant Cardiologist at UCLH and Barts Health NHS Trusts, and a Visiting Scientist at the Broad Institute of MIT and Harvard. He serves as Principal Investigator for the HERMES Consortium, a global collaboration focused on heart failure genetics, and Co-Director of the Rare Disease Research UK Cardiovascular Initiative.

His research focuses on understanding the genetic basis of cardiomyopathy and heart failure to uncover novel disease mechanisms and advance diagnosis and treatment. Dr. Lumbers integrates multi-omic data to identify potential therapeutic targets, recently collaborating with Pfizer through an Innovative Target Exploration Network partnership. He also develops scalable and computable cardiovascular disease phenotypes to enable effective use of large healthcare data resources for genetic research.

Analysis of Dr. Lumbers' recent publications reveals a strong emphasis on cardiovascular genetics, particularly genome-wide association studies of heart failure and cardiomyopathy. His work bridges clinical cardiology with advanced computational methods, including deep learning applications in medical imaging and development of reproducible phenotyping algorithms for large-scale biobank data. A notable trend is his focus on translating genetic discoveries into clinical applications through partnerships with organizations like the European Society of Cardiology.

• Principal Investigator, HERMES Consortium (global heart failure genetics collaboration)
• Co-Director, Rare Disease Research UK Cardiovascular Initiative
• Co-Director, Applied Computational Genomics Module for the MSc in Health Data Science
• Collaborator with European Society of Cardiology on computable clinical guidelines
• NIH-funded platform development for pan-biobank genetic study of cardiomyopathies

Dr. Lumbers leads the HERMES Consortium, an international collaboration that has delivered the first large genome-wide association studies of heart failure conditions. His team has identified that almost a third of dilated cardiomyopathy is polygenic. Through the Rare Disease Research UK Cardiovascular Initiative, they are building a national data platform by unlocking NHS genetic and phenotype data for research purposes.